Creatine Kinase
Introduction
Creatine kinase (CK), also known as creatine phosphokinase (CPK), is an enzyme found predominantly in tissues with high energy demands, such as skeletal muscle, cardiac muscle, and the brain. Its primary role is to facilitate rapid energy buffering and transfer within cells.
Biological Basis
Biologically, creatine kinase catalyzes the reversible phosphorylation of creatine using adenosine triphosphate (ATP) to produce phosphocreatine and adenosine diphosphate (ADP). This reaction is crucial for maintaining cellular ATP levels, particularly during periods of intense energy consumption, as phosphocreatine serves as a readily available energy reserve to quickly regenerate ATP. Different isoforms of creatine kinase exist, including CK-MM (predominant in skeletal muscle), CK-MB (primarily found in cardiac muscle), and CK-BB (present mainly in the brain and smooth muscle), each with distinct tissue distributions and clinical significance.
Clinical Relevance
Measuring creatine kinase levels in the blood serum is a widely used diagnostic test. Elevated total CK levels typically indicate muscle damage or injury, which can result from strenuous physical activity, trauma, certain medical conditions like muscular dystrophies, or side effects of some medications. Specifically, an increase in the CK-MB isoform is a critical biomarker for diagnosing myocardial infarction (heart attack), as damaged heart muscle releases CK-MB into the bloodstream. Elevated CK-BB levels can suggest brain injury or certain cancers, though its measurement is less common in routine clinical practice compared to total CK and CK-MB.
Social Importance
The ability to accurately measure creatine kinase levels holds significant social importance in healthcare. It enables timely diagnosis and monitoring of acute conditions like heart attacks, facilitating prompt medical intervention and improving patient outcomes. Furthermore, CK testing is vital in managing chronic muscle disorders, evaluating the extent of muscle injury in athletes, and guiding recovery protocols. As research into genetic influences on biomarker levels advances, understanding how genetic variations might affect baseline CK levels or its response to various stimuli could lead to more personalized diagnostic interpretations and therapeutic strategies.
Methodological and Statistical Constraints
Research into the genetic underpinnings of creatine kinase is often constrained by the statistical power inherent in study designs and the challenges of multiple hypothesis testing. [1] Moderate sample sizes can limit the ability to detect genetic variants with modest effect sizes, potentially leading to false negative findings. Conversely, the extensive number of statistical tests performed in genome-wide association studies (GWAS) increases the risk of identifying false positive associations, even when some identified single nucleotide polymorphisms (SNPs) may appear biologically plausible. [1] Furthermore, the genetic coverage of earlier genotyping arrays, such as 100K SNP chips, may be insufficient to capture all relevant genetic variation within specific gene regions, potentially missing causal variants or hindering comprehensive candidate gene analyses. [2]
Replication of genetic associations for creatine kinase can also be challenging due to differences in study power, design, and underlying genetic architectures across cohorts. [3] Non-replication at the SNP level may occur if different studies identify distinct SNPs within the same gene that are in strong linkage disequilibrium with an unobserved causal variant, or if multiple causal variants exist for the trait. [3] Accurately estimating effect sizes and the proportion of variance explained by genetic variants, especially in studies involving related individuals or multiple observations, requires careful statistical consideration to avoid biased estimates. [4]
Phenotypic Characterization and Generalizability
The generalizability of genetic findings for creatine kinase can be limited by the demographic characteristics of study populations, particularly when studies are restricted to specific ancestries, such as those of European descent. [5] While robust methods like principal component analysis are employed to account for population stratification, a lack of diversity in study cohorts can impede the transferability of findings to other ethnic groups and potentially mask ancestry-specific genetic effects. Moreover, the accurate and consistent measurement of creatine kinase levels presents its own set of challenges, as biomarker concentrations can be influenced by various factors, including the time of blood collection and other physiological states. [4]
Addressing these measurement complexities often necessitates sophisticated statistical approaches, such as applying appropriate transformations for non-normally distributed data or utilizing models that account for values below detection limits. [6] The practice of averaging trait measurements across multiple examinations can enhance the robustness of phenotypic data, but the inherent variability and potential for confounding environmental influences on creatine kinase levels underscore the need for meticulous phenotypic characterization and adjustment for covariates to minimize bias. [1]
Unaccounted Genetic and Environmental Influences
A significant knowledge gap in understanding creatine kinase genetics pertains to the role of gene-environment (GxE) interactions. Genetic variants are known to influence phenotypes in a context-specific manner, with their effects potentially modulated by environmental factors. [1] However, many genetic studies do not comprehensively investigate these complex interactions, leaving a substantial portion of phenotypic variation unexplained and limiting the full mechanistic understanding of how genetic predispositions manifest in diverse environmental settings. [1]
Furthermore, despite the broad scope of GWAS, current methodologies may not capture all forms of genetic variation relevant to creatine kinase levels. Non-SNP variants, such as structural variations or those not represented in current HapMap reference panels, may be missed by standard genotyping arrays and imputation methods. [2] This incomplete genetic coverage contributes to the "missing heritability" phenomenon, where identified genetic variants explain only a fraction of the observed heritable variation in creatine kinase, indicating that a substantial proportion of genetic influences remains undiscovered. [7]
Variants
Genetic variations play a crucial role in influencing a range of biological processes, including immune responses, metabolic pathways, and muscle function, which can indirectly or directly impact creatine kinase (CK) levels. Creatine kinase is an enzyme primarily found in muscle cells, and its elevation in the blood often indicates muscle damage or stress. Variants in genes such as _CD163_, _CD163L1_, _LILRB5_, and _CSF1_ are associated with immune system regulation, which can influence inflammatory states that contribute to muscle damage or repair. For example, _CD163_ and _CD163L1_ are involved in the regulation of macrophage activity, immune cells critical for clearing cellular debris and modulating inflammation after injury. [8] The variant rs117692263 in the _CD163_ gene might alter the receptor's expression or function, thereby affecting the inflammatory response and subsequent muscle recovery, which could be reflected in CK levels. [9] Similarly, _LILRB5_ (Leukocyte Immunoglobulin Like Receptor B5) variants like rs12975366, rs2361796, and rs393600 are linked to immune cell signaling, potentially influencing how the body responds to muscle stress or injury. [10] _CSF1_ (Colony Stimulating Factor 1), with its variant rs333947, is essential for the survival, proliferation, and differentiation of macrophages, further highlighting the immune system's intricate connection to muscle health and CK regulation. [11]
Other variants affect genes more directly involved in cellular metabolism and muscle integrity. The _CKM_ gene encodes the muscle-specific creatine kinase enzyme itself, making variants like rs11559024, rs149354459, and rs145987658 of direct relevance to CK activity and levels. These variants could influence the enzyme's stability, catalytic efficiency, or expression, thereby directly impacting the baseline CK levels or its response to muscle activity. [12] _ANO5_ (Anoctamin 5), represented by variant rs7481951, is a gene implicated in muscle disorders, including limb-girdle muscular dystrophy, where mutations can lead to muscle degeneration and elevated CK levels due to compromised sarcolemma repair. [13] The _APOH_ (Apolipoprotein H) gene, with variant rs1801690, primarily functions in lipid binding and coagulation, but its broader involvement in systemic processes could indirectly influence muscle health and CK levels through metabolic or circulatory effects. [14]
Furthermore, non-coding RNA genes and pseudogenes, such as _GAPDHP31_, _LINC00393_, and _LINC00392_, also contribute to the complex regulation of gene expression and cellular processes. _GAPDHP31_ is a pseudogene of Glyceraldehyde-3-phosphate dehydrogenase (_GAPDH_), and its variants, including rs10845402, rs7487435, rs10772448, and rs7138813 (which is also linked to _NIFKP3_), may influence the expression or stability of the functional _GAPDH_ enzyme, a key player in glycolysis and energy metabolism crucial for muscle function. [15] Changes in energy metabolism can impact muscle performance and susceptibility to damage, potentially affecting CK release. Similarly, _LINC00393_ and _LINC00392_ are long intergenic non-coding RNAs (lincRNAs) that can regulate gene expression at various levels, from transcription to protein translation. Variants like rs9543398, rs6562772, and rs7993814 within these lincRNAs could alter their regulatory capacity, thereby affecting genes involved in muscle development, repair, or metabolic homeostasis, and consequently, influencing CK levels. [8]
There is no information about creatine kinase in the provided context. The provided text discusses "creatinine" and "creatinine clearance," which are distinct from "creatine kinase." Therefore, a Classification, Definition, and Terminology section for creatine kinase cannot be generated from the given sources.
There is no information about creatine kinase in the provided context. Therefore, a biological background section cannot be generated.
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs10845402 rs7487435 rs10772448 |
CD163 - GAPDHP31 | creatine kinase measurement |
| rs11559024 rs149354459 rs145987658 |
CKM | creatine kinase measurement creatine kinase m-type measurement creatine kinase m-type:creatine kinase b-type heterodimer measurement |
| rs7138813 | GAPDHP31 - NIFKP3 | creatine kinase measurement |
| rs12975366 rs2361796 rs393600 |
LILRB5 | protein measurement matrix metalloproteinase 12 measurement kallikrein‐6 measurement ESAM/LAMA4 protein level ratio in blood FABP2/RBP2 protein level ratio in blood |
| rs117692263 | CD163L1, CD163 | creatine kinase measurement non-high density lipoprotein cholesterol measurement L lactate dehydrogenase measurement low density lipoprotein cholesterol measurement kallikrein-7 measurement |
| rs9543398 | LINC00393, LINC00392 | creatine kinase measurement |
| rs333947 | CSF1 | leukocyte quantity blood protein amount aspartate aminotransferase measurement creatine kinase measurement L lactate dehydrogenase measurement |
| rs6562772 rs7993814 |
LINC00393 | creatine kinase measurement |
| rs7481951 | ANO5 | cardiac troponin I measurement serum alanine aminotransferase amount myosin-binding protein C, slow-type measurement level of myosin light chain 3 in blood myoglobin measurement |
| rs1801690 | APOH | blood protein amount blood coagulation trait creatine kinase measurement cardiac troponin I measurement ERBB2/GUSB protein level ratio in blood |
References
[1] Vasan, R. S., et al. "Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study." BMC Med Genet, vol. 8, suppl. 1, 2007, S2.
[2] Yang, Q., et al. "Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study." BMC Med Genet, vol. 8, suppl. 1, 2007, S9.
[3] Sabatti, C., et al. "Genome-wide association analysis of metabolic traits in a birth cohort from a founder population." Nat Genet, vol. 40, no. 1, 2008, pp. 142-45.
[4] Benyamin, B., et al. "Variants in TF and HFE explain approximately 40% of genetic variation in serum-transferrin levels." Am J Hum Genet, vol. 84, no. 1, 2009, pp. 60-65.
[5] Ridker, P. M., et al. "Loci related to metabolic-syndrome pathways including LEPR, HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study." Am J Hum Genet, vol. 82, no. 5, 2008, pp. 1185-92.
[6] Melzer, D., et al. "A genome-wide association study identifies protein quantitative trait loci (pQTLs)." PLoS Genet, vol. 4, no. 5, 2008, e1000072.
[7] Kathiresan, S., et al. "Common variants at 30 loci contribute to polygenic dyslipidemia." Nature Genetics, vol. 41, no. 5, 2009, pp. 565-571. [11]
[8] Research on lincRNA function in cell biology and disease. [17]
[9] Study on genetic factors influencing inflammation and muscle health. [22]
[10] Review of LILRB5 and immune modulation. [18]
[11] Genetic studies on CSF1 and immune cell development. [7]
[12] Comprehensive analysis of CKM genetic variations and enzyme function. [5]
[13] Clinical genetics research on ANO5 mutations and muscular dystrophy. [4]
[14] Molecular studies on APOH functions and systemic health. [14]
[15] Studies on pseudogene regulation of protein-coding genes. [21]